Sei Investments Co. Trims Stock Holdings in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

Sei Investments Co. lowered its holdings in Turning Point Therapeutics, Inc. (NASDAQ:TPTX) by 1.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,507 shares of the company’s stock after selling 306 shares during the period. Sei Investments Co.’s holdings in Turning Point Therapeutics were worth $1,210,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of TPTX. Dimensional Fund Advisors LP purchased a new position in Turning Point Therapeutics in the fourth quarter valued at about $2,950,000. Alliancebernstein L.P. boosted its holdings in Turning Point Therapeutics by 11.7% in the first quarter. Alliancebernstein L.P. now owns 1,055,886 shares of the company’s stock valued at $99,876,000 after purchasing an additional 110,475 shares during the last quarter. Blueshift Asset Management LLC purchased a new position in Turning Point Therapeutics in the first quarter valued at about $279,000. Arizona State Retirement System lifted its holdings in Turning Point Therapeutics by 3.4% during the 1st quarter. Arizona State Retirement System now owns 11,920 shares of the company’s stock worth $1,128,000 after buying an additional 392 shares during the last quarter. Finally, The PNC Financial Services Group Inc. lifted its holdings in Turning Point Therapeutics by 9.9% during the 1st quarter. The PNC Financial Services Group Inc. now owns 5,120 shares of the company’s stock worth $484,000 after buying an additional 460 shares during the last quarter. 92.32% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP Annette North sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 30th. The stock was sold at an average price of $80.00, for a total value of $800,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Andrew John Partridge sold 1,869 shares of Turning Point Therapeutics stock in a transaction on Wednesday, July 14th. The shares were sold at an average price of $74.90, for a total value of $139,988.10. Following the transaction, the executive vice president now owns 21,767 shares in the company, valued at $1,630,348.30. The disclosure for this sale can be found here. Company insiders own 7.30% of the company’s stock.

TPTX has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $178.00 target price on shares of Turning Point Therapeutics in a report on Tuesday, August 10th. Zacks Investment Research raised Turning Point Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 10th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Turning Point Therapeutics currently has a consensus rating of “Buy” and an average price target of $150.00.

Shares of NASDAQ TPTX opened at $78.89 on Tuesday. The company has a market cap of $3.90 billion, a price-to-earnings ratio of -23.83 and a beta of 1.00. Turning Point Therapeutics, Inc. has a 12-month low of $59.73 and a 12-month high of $141.30. The stock’s 50 day simple moving average is $70.69 and its 200 day simple moving average is $76.76.

Turning Point Therapeutics (NASDAQ:TPTX) last announced its quarterly earnings results on Monday, August 9th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.06. During the same period in the prior year, the company posted ($0.82) earnings per share. Equities research analysts forecast that Turning Point Therapeutics, Inc. will post -4.51 earnings per share for the current year.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor.

Further Reading: What is the Federal Reserve?

Want to see what other hedge funds are holding TPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Turning Point Therapeutics, Inc. (NASDAQ:TPTX).

Institutional Ownership by Quarter for Turning Point Therapeutics (NASDAQ:TPTX)

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.